Northern Trust
FDMT icon

Northern Trust’s 4D Molecular Therapeutics FDMT Stock Holding History

Northern Trust’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.49M Buy
562,929
+220,895
+65% +$2.15M ﹤0.01% 2375
2026
Q1 		$3.18M Buy
342,034
+28,214
+9% +$246K ﹤0.01% 2705
2025
Q4 		$2.35M Sell
313,820
-21,766
-6% -$221K ﹤0.01% 2902
2025
Q3 		$2.92M Buy
335,586
+6,611
+2% +$39.5K ﹤0.01% 2825
2025
Q2 		$1.22M Sell
328,975
-51,945
-14% -$183K ﹤0.01% 3283
2025
Q1 		$1.23M Sell
380,920
-59,745
-14% -$281K ﹤0.01% 3190
2024
Q4 		$2.45M Buy
440,665
+9,982
+2% +$78.3K ﹤0.01% 2907
2024
Q3 		$4.66M Buy
430,683
+63,204
+17% +$1.05M ﹤0.01% 2516
2024
Q2 		$7.71M Sell
367,479
-6,703
-2% -$168K ﹤0.01% 2143
2024
Q1 		$11.9M Buy
374,182
+8,839
+2% +$226K ﹤0.01% 1931
2023
Q4 		$7.4M Buy
365,343
+1,618
+0.4% +$21.3K ﹤0.01% 2265
2023
Q3 		$4.63M Buy
363,725
+31,358
+9% +$524K ﹤0.01% 2488
2023
Q2 		$6.01M Buy
332,367
+57,938
+21% +$1.07M ﹤0.01% 2411
2023
Q1 		$4.72M Sell
274,429
-392
-0.1% -$7.62K ﹤0.01% 2503
2022
Q4 		$6.1M Sell
274,821
-1,859
-0.7% -$28.7K ﹤0.01% 2363
2022
Q3 		$2.22M Buy
276,680
+2,349
+0.9% +$21.3K ﹤0.01% 2965
2022
Q2 		$1.92M Buy
274,331
+15,051
+6% +$146K ﹤0.01% 3092
2022
Q1 		$3.92M Buy
259,280
+4,908
+2% +$77.1K ﹤0.01% 2730
2021
Q4 		$5.58M Buy
254,372
+64,547
+34% +$1.58M ﹤0.01% 2620
2021
Q3 		$5.12M Buy
189,825
+91,297
+93% +$2.6M ﹤0.01% 2715
2021
Q2 		$2.37M Buy
98,528
+11,385
+13% +$349K ﹤0.01% 3276
2021
Q1 		$3.78M Buy
+87,143
New +$3.86M ﹤0.01% 2914

Other funds holding FDMT

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Northern Trust's FDMT Position: Q2 2026 in Review

Northern Trust increased its 4D Molecular Therapeutics (FDMT) stake by 65% in Q2 2026, buying an estimated $2.15M and bringing the position to 562,929 shares worth $7.49M. The position accounts for ﹤0.01% of the portfolio, ranked #2375.

Northern Trust first reported a position in FDMT in Q1 2021 and has held it in 22 quarters since. The position peaked at $11.9M in Q1 2024. 157 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • Northern Trust held 562,929 shares of 4D Molecular Therapeutics worth $7.49M as of Q2 2026.
  • Northern Trust bought 220,895 4D Molecular Therapeutics shares in Q2 2026, an estimated $2.15M.
  • 4D Molecular Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q2 2026, its #2375 holding.
  • Northern Trust first reported a position in 4D Molecular Therapeutics in Q1 2021 and has held it in 22 quarters since.
  • Northern Trust's 4D Molecular Therapeutics position peaked at $11.9M in Q1 2024.
  • 157 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Northern Trust's 13F filing for Q2 2026, filed 13 Aug 2026.